288 related articles for article (PubMed ID: 33337340)
21. Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.
Jeong CW; Lee S; Jung JW; Lee BK; Jeong SJ; Hong SK; Byun SS; Lee SE
PLoS One; 2014; 9(4):e94441. PubMed ID: 24710020
[TBL] [Abstract][Full Text] [Related]
22. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract][Full Text] [Related]
25. Are prostate biopsies necessary for all patients 75years and older?
Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
[TBL] [Abstract][Full Text] [Related]
26. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
[TBL] [Abstract][Full Text] [Related]
27. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
28. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
Wu YS; Zhang N; Liu SH; Xu JF; Tong SJ; Cai YH; Zhang LM; Bai PD; Hu MB; Jiang HW; Na R; Ding Q; Sun YH
Asian J Androl; 2016; 18(6):925-929. PubMed ID: 27212127
[TBL] [Abstract][Full Text] [Related]
29. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
30. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
31. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
Louie KS; Seigneurin A; Cathcart P; Sasieni P
Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
[TBL] [Abstract][Full Text] [Related]
32. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
33. European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.
Gómez-Gómez E; Carrasco-Valiente J; Blanca-Pedregosa A; Barco-Sánchez B; Fernandez-Rueda JL; Molina-Abril H; Valero-Rosa J; Font-Ugalde P; Requena-Tapia MJ
Urology; 2017 Apr; 102():85-91. PubMed ID: 27840252
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
[TBL] [Abstract][Full Text] [Related]
35. Validating the European randomised study for screening of prostate cancer (ERSPC) risk calculator in a contemporary South African cohort.
Kowlessur B; Phull M; Patel B; Henry M; Lazarus J
World J Urol; 2020 Jul; 38(7):1711-1718. PubMed ID: 31522234
[TBL] [Abstract][Full Text] [Related]
36. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
37. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.
Strobl AN; Thompson IM; Vickers AJ; Ankerst DP
J Urol; 2015 Jul; 194(1):58-64. PubMed ID: 25636656
[TBL] [Abstract][Full Text] [Related]
38. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
[TBL] [Abstract][Full Text] [Related]
39. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]